News

Eli Lilly's experimental GLP-1 pill may rival Ozempic and Wegovy? Check how much weight you could lose
Eli Lilly's experimental weight loss pill, orforglipron, demonstrated an average weight loss of 12% in a late-stage trial, ...
Eli Lilly second quarter earnings beat on strong GLP-1 sales, but stock dives on GLP-1 pill trial results
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Daily oral GLP-1 pill could be just as effective as weekly shots: Drugmaker
Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.
Can Eli Lilly keep its GLP-1 crown? Q2 earnings will tell
Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.
Fierce Pharma1d
Novo's outgoing CEO prepares to hand off business as sales threats from Lilly, GLP-1 compounders persist
On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...
GLP-1 "Arms Race" Broadens to Include Dozens of Companies
Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / ...
Eli Lilly raises 2025 revenue guidance to $60B-$62B while expanding GLP-1 pipeline and production
Q2 2025 Management View CEO David A. Ricks highlighted a strong quarter, stating, "Q2 was a strong quarter. We delivered robust revenue growth, shared top line clinical data from multiple Phase III ...